Clinical trial
REFINE: Regorafenib Observational Study in Hepatocellular Carcinoma
NCT03289273 is registered in ClinicalTrials.gov with Bayer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- REFINE: Regorafenib Observational Study in Hepatocellular Carcinoma
- Lead sponsor
- Bayer
- Phase
- Observational
- Overall status
- Completed
- Start date
- September 13, 2017
- Completion date
- June 21, 2022
- Enrollment
- 1,010 (actual)
- Sites
- 37
Conditions
As the registry lists them; a condition with its own page is linked.